We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Evoqua Water Technologies Corp. (“Evoqua” or the “Company”) (NYSE: AQUA) in connection with the proposed acquisition of the Company by Xylem Inc. (“Xylem”) (NYSE: XYL).  Under the merger agreement, the Company’s shareholders will receive 0.480 shares of Xylem common stock for each Evoqua share, representing implied per-share consideration of $52.89 based upon Xylem’s January 20, 2023 closing price of $110.18.  The transaction is valued at approximately $7.5 billion.

Weiss Law is investigating whether (i) Evoqua’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates Evoqua’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.